Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00150254 · ClinicalTrials.gov registry record · Phase 2
12 Week Evaluation of the Safety and Efficacy of 4 Dosing Strategies of CP-526,555 and Placebo for Smoking Cessation.
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 625
- Enrollment target
NCT00150254: Completed Phase 2 study, sponsored by Pfizer.
NCT00150254 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 625 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (370% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00150254, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 625 participants
- Enrollment target
Study Summary
The purpose of the study is to measure the safety and efficacy of four dosing strategies of CP-526,555 for 12 weeks compared with placebo for smoking cessation. Post-treatment follow-up of smoking status to one year from randomization was performed in a non-treatment extension Protocol A3051018
Interventions
- DRUG CP-526,555 (varenicline)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 625 participants |
| Start Date | 2001-09 |
| Est. Completion | 2002-10 |
| Phase | Phase 2 |
What the finished NCT00150254 record still lists
NCT00150254 is an interventional study that assigns participants to a tested intervention. The registered 625 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (370% higher).
The record links to 0 conditions, and to 1 intervention - of which CP-526,555 (varenicline) is the first listed.
NCT00150254 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00150254 about?
NCT00150254 is a clinical study titled "12 Week Evaluation of the Safety and Efficacy of 4 Dosing Strategies of CP-526,555 and Placebo for Smoking Cessation.". The purpose of the study is to measure the safety and efficacy of four dosing strategies of CP-526,555 for 12 weeks compared with placebo for smoking cessation. Post-treatment follow-up of smoking status to one year from randomization was performed in a non-treatment extension Protocol A3051018
What is the current status of trial NCT00150254?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 625 participants. The study started on 2001-09. Estimated completion is 2002-10.
What interventions are being tested in trial NCT00150254?
The interventions under investigation include: CP-526,555 (varenicline) (DRUG).
Who is sponsoring clinical trial NCT00150254?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00150254's enrollment target sits among peer trials
625 52nd of 2000 higher than 1,949 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05349227 · 625 participants · NA
Comprehensive Outcomes for After Cancer Health
- NCT06103864 · 625 participants · Phase 3
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
- NCT06230510 · 625 participants · NA
Milk-Tot Study: Impact of Whole Versus Low-fat Milk on Child Health
- NCT06677112 · 625 participants · NA
MCC-24-GYN-11: Comparison of Nodal Sampling in Endometrial Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia